Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ADP Report Better than Expected

by Zacks Equity Research

ADP Report Better than Expected

Gilead Sciences (GILD) Stock Moves -1.54%: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $74.76, marking a -1.54% move from the previous day.

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

Gilead Expands Access to Experimental Coronavirus Treatment

by Zacks Equity Research

Gilead (GILD) looks to expand access programs to accelerate access to remdesivir for COVID-19 patients.

Sejuti Banerjea headshot

COVID-19 Claiming Lives But Therapeutics Could Be on the Way

by Sejuti Banerjea

The WHO's Solidarity testing project could be good news for the world.

Sanofi Begins Kevzara Study for Severe Coronavirus Infection

by Zacks Equity Research

Sanofi (SNY) begins treatment in a second phase II/III study evaluating its rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19 outside the United States.

The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences

Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir

by Zacks Equity Research

Gilead (GILD) asks the FDA to revoke the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.

Biotech Stocks Accelerate Efforts for Coronavirus Treatments

by Zacks Equity Research

Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals

Daniel Laboe headshot

How To Play The W-Shaped Recovery

by Daniel Laboe

Patience is the name of the game during market downturns

Daniel Laboe headshot

Top 5 Drug Stocks To Stop The Coronavirus Pandemic

by Daniel Laboe

It is only a matter of time before this virus anxiety is a thing of the past.

Coronavirus Drug Development Race to Boost These 4 Stocks

by Zacks Equity Research

Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.

Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Kinjel Shah headshot

Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure

by Kinjel Shah

Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval.

Roche Gets FDA Approval for Actemra Trials in COVID-19

by Zacks Equity Research

Roche (RHHBY) gets FDA nod to evaluate Actemra plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.

Kinjel Shah headshot

Glaxo's Long-Acting HIV Regimen Cabenuva Gets Canada's Nod

by Kinjel Shah

Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults

Novartis to Donate Generic Hydroxychloroquine for Coronavirus

by Zacks Equity Research

Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.

Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group

by Zacks Equity Research

The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.

Ekta Bagri headshot

Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus

by Ekta Bagri

Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $78.55 in the latest trading session, marking a -1.1% move from the prior day.

Ekta Bagri headshot

Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?

by Ekta Bagri

Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.

The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA

by Zacks Equity Research

The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA

Kinjel Shah headshot

Pfizer, Regeneron Give Update on Coronavirus Drug Development

by Kinjel Shah

Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.

Regeneron Up on Identification of Antibodies for Coronavirus

by Zacks Equity Research

Regeneron (REGN) announces identification of antibodies from its VelocImmune mice for the treatment of coronavirus.